Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Onco-Innovations Ltd. ( (TSE:ONCO) ) has provided an update.
Onco-Innovations Limited has announced a collaboration with Kuano Ltd. to accelerate the development of its PNKP Inhibitor Technology using advanced AI and quantum drug discovery methods. This partnership aims to enhance Onco’s proprietary PNKP inhibitor platform by integrating Kuano’s quantum molecular modeling, which will provide detailed insights into PNKP inhibition. The initiative is expected to streamline the path from modeling to validation and synthesis, potentially leading to the creation of next-generation therapeutics and strengthening Onco’s position in next-generation oncology.
More about Onco-Innovations Ltd.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company focuses on the prevention and treatment of cancer through pioneering research and innovative solutions, holding an exclusive worldwide license to patented technology targeting solid tumors.
Average Trading Volume: 37,832
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$79.79M
Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.